Výsledky vyhledávání - "M. R. Bongioanni"

Modified and improved anti-acetylcholine receptor (AChR) antibody assay: comparison of analytical and clinical performance with conventional anti-AChR antibody assay

Autor: Luca Durelli, Roberto Pagni, Bruno Bergamasco, L. Bergamini, Giuseppe Aimo, M. R. Bongioanni, B. Ferrero

Publikováno v: Clinical Chemistry. 43:824-831

We developed a modified anti-acetylcholine receptor (AChR) antibody (Ab) assay based on a radioreceptor assay and a calibration curve. We compared the analytical and clinical performances of this modified assay with those of the conventional anti-ACh

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fe7ae74c8ae91c11bc9326fc6be95c88
https://doi.org/10.1093/clinchem/43.5.824

Zobrazit plný text záznamu

Autoimmune events during interferon beta-1b treatment for multiple sclerosis

Autor: M.A Biava, M. R. Bongioanni, Giorgio Maria Saracco, L Giorda, A. Oggero, A. Ricci, Luca Durelli, Bruno Bergamasco, P.C. Brossa, E Gentile, E. Verdun, G. Aimo, R Pagni, Eugenia Rota, B. Ferrero, Marilena Durazzo, G. Isoardo

Publikováno v: Journal of the neurological sciences. 162(1)

Autoimmune events, although rarely reported during interferon beta-1b (IFNB) treatment of relapsing-remitting (RR) multiple sclerosis (MS), may be more frequent than expected due to the many immunologic abnormalities associated with this disease. We

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8c6614985ef507193c5a19e1749fd51
https://pubmed.ncbi.nlm.nih.gov/10064173

Zobrazit plný text záznamu

Modified and improved anti-acetylcholine receptor (AchR) antibody assay: comparison of analytical and clinical performance with conventional anti-AChR antibody assay

Autor: B, Ferrero, G, Aimo, R, Pagni, B, Bergamasco, M R, Bongioanni, L, Bergamini, L, Durelli

Publikováno v: Clinical chemistry. 43(5)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::908c3bb2d8914306039cc15bf3e91c86
https://pubmed.ncbi.nlm.nih.gov/9166237

Zobrazit plný text záznamu

Systemic high-dose recombinant-alpha-2a-interferon therapy modulates lymphokine production in multiple sclerosis

Autor: A. Oggero, Luca Durelli, Daniele Imperiale, Bruno Bergamasco, M. R. Bongioanni, B. Ferrero, Roberto Pagni, E. Verdun, M. Geuna, Giuseppe Aimo

Publikováno v: Journal of the neurological sciences. 143(1-2)

Chronic systemic high-dose recombinant alpha2a-interferon (rIFNA) therapy reduces exacerbation rate and MRI signs of disease activity in relapsing/remitting multiple sclerosis (RR MS) patients. In order to clarify the possible mechanisms underlying t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c6524c0801c3d0442e635a9f76cda6b
https://pubmed.ncbi.nlm.nih.gov/8981304

Zobrazit plný text záznamu

Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis: Disease activity resumes after stopping treatment

Autor: Daniele Imperiale, R. Ferri, M. R. Bongioanni, Gianni Boris Bradac, M. Geuna, Luca Durelli, Bruno Bergamasco, L. Bergamini, B. Ferrero, Mauro Bergui

We evaluated the long-lasting effects of systemic high-dose recombinant interferon alpha-2a (rIFNA) in relapsing-remitting (RR) MS after discontinuing treatment in a single-blind randomized placebo-controlled trial with 20 RR clinically definite MS p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc6bcb41fbd9e6e5c1095a16aed26c9c
http://hdl.handle.net/2318/49486

Zobrazit plný text záznamu

Chronic systemic high‐dose recombinant interferon alfa‐2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing‐remitting multiple sclerosis

Autor: B. Ferrero, Gianni Boris Bradac, A. Riva, Luca Durelli, L Bergamini, M. R. Bongioanni, M. Geuna, M. F. Ferrio, R. Ferri, Bruno Bergamasco, S. Vai, R. Cavallo

Publikováno v: Neurology. 44:406-406

We report a randomized, double-blind, placebo-controlled pilot trial of systemic high-dose recombinant interferon alfa-2a (rIFNA) in 20 patients with relapsing-remitting (RR) multiple sclerosis (MS). Patients received 9 million IU rIFNA (n = 12) or p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7fa5a0e2a29fb101fee1d6d00b17ccd
https://doi.org/10.1212/wnl.44.3_part_1.406

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání